New XOMA Antibodies Unveiled At The Society For Immunotherapy Of Cancer 31st Annual Meeting

  • Preclinical Data from XOMA's Novel Anti-IL-2 Immuno-oncology Monoclonal Antibodies Program to be Presented at SITC
  • Advancing Unique Functional Antibody Antagonists Targeting the Parathyroid Hormone Receptor 1 (PTH1R)
  • Plan to Out-license IL-2 and PTH1R Programs to Fund Endocrine Efforts

BERKELEY, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today unveiled its interleukin-2 (IL-2) monoclonal antibody program, a series of novel agents from its scientific discovery research unit, and announced the advancement of its parathyroid hormone receptor 1 (PTH1R) antibody antagonists program.  These novel monoclonal antibodies are further examples of the capability of XOMA's antibody platform and its expertise in the identification of novel oncology and oncology-related candidates with potential to positively affect outcomes in cancer patients.

"With our strategic focus on advancing our endocrine programs, we continue to seek ways to support and fund these efforts through discovery and licensing of our non-endocrine assets.  For our oncology antibodies, we seek partners who have a deep commitment to and expertise in oncology drug development.  An example of this is the TGF-beta antibody program that we licensed to Novartis last year, which we believe is advancing rapidly to initiation of clinical studies in the near future," said John Varian, Chief Executive Officer of XOMA.  "We have unique expertise in creating new antibodies to treat a variety of cancers and the side effects associated with currently marketed therapies.  As with our TGF-beta antibody program, we plan to out-license our IL-2 and PTH1R antibody programs to organizations that can rapidly advance them into clinical development."

IL-2 Monoclonal Antibodies ProgramImmune checkpoint inhibitors are transforming cancer treatment and revitalizing interest in immunotherapies.  While efficacy has been observed in patients with advanced metastatic disease treated with checkpoint inhibitors, not all patients respond, and most responses are incomplete.  Preclinical studies suggest that combining additional modalities with checkpoint inhibitors will provide opportunities to improve patient outcomes. 

"IL-2 has long been recognized as an effective therapy for metastatic melanoma and renal cell carcinoma, but it has serious dose-limiting toxicities that prevent broad clinical use.  We generated novel antibodies that, when given with IL-2, are intended to steer IL-2 to enhance its positive impact with less toxicity, potentially improving the therapeutic index over standard IL-2 therapy," commented Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer of XOMA.

If you liked this article you might like

XOMA (XOMA) Weak On High Volume

Xoma Stock Soaring on Q4 Earnings Beat

Xoma Stock Surges in After-Hours Trading on Q4 Results

Friday Small-Cap Focus: Xoma

Friday Small-Cap Focus: Xoma

Xoma Stock Surges, Sells Diabetes Treatment to Novo Nordisk for $295 Million